| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03405103 |
| P932 | PMC publication ID | 6979812 |
| P2093 | author name string | Samuel S. Lee | |
| Kelly W. Burak | |||
| P2860 | cites work | Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C | Q73091547 |
| Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon‐Resistant Chronic Hepatitis C | Q73501463 | ||
| Treatment of chronic hepatitis C with amantadine | Q73671703 | ||
| National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C | Q73717356 | ||
| Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials | Q73717402 | ||
| Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C | Q73907321 | ||
| Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon | Q74310654 | ||
| Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study | Q77637898 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group | Q29620719 | ||
| Future directions in the treatment of patients with chronic hepatitis C virus infection. | Q33547316 | ||
| Hepatitis C: epidemiology and review of complementary/alternative medicine treatments | Q33723514 | ||
| Hepatitis C: the clinical spectrum of the disease | Q33809411 | ||
| New treatment strategies in non-responder patients with chronic hepatitis C. | Q33809555 | ||
| Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. | Q34466343 | ||
| Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. | Q36865888 | ||
| Management of viral hepatitis: clinical and public health perspectives--a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver | Q41586892 | ||
| A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy | Q41645700 | ||
| Re-treatment of chronic hepatitis C with consensus interferon . | Q42675525 | ||
| Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study | Q42980410 | ||
| Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial | Q42981402 | ||
| Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group | Q42984083 | ||
| Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration | Q42985145 | ||
| Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy | Q42985646 | ||
| Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group | Q42986315 | ||
| Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B. | Q42986395 | ||
| Review article: interferon and hepatitis C--factors predicting therapeutic outcome | Q42989240 | ||
| Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. | Q42989774 | ||
| Consensus interferon: a novel interferon for the treatment of hepatitis C. | Q42990674 | ||
| Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results | Q42991088 | ||
| Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load | Q42993939 | ||
| Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators | Q42995529 | ||
| A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia | Q42995701 | ||
| Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients | Q42995718 | ||
| Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group | Q42996746 | ||
| Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone | Q43037990 | ||
| Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients | Q44673247 | ||
| Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial | Q45297184 | ||
| Hepatitis C in the patient with human immunodeficiency virus infection | Q45752014 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. | Q50587404 | ||
| Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. | Q50587547 | ||
| Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. | Q50587659 | ||
| Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. | Q50650208 | ||
| Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. | Q50851322 | ||
| Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. | Q50994209 | ||
| Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. | Q52249518 | ||
| Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration | Q71650797 | ||
| Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study | Q71950837 | ||
| Ten year follow-up of patients with chronic hepatitis C treated with interferon | Q73084531 | ||
| P433 | issue | Suppl 1 | |
| P304 | page(s) | S24-S28 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Canadian Journal of Public Health | Q15752348 |
| P1476 | title | Treatment Options in Patients with Chronic Hepatitis C | |
| P478 | volume | 91 |
Search more.